New Ways to Treat HCV Infection After Liver Transplant

New direct-acting agents against hepatitis C virus (HCV) can cure the infection when it recurs in patients with liver transplants. Researchers reported findings from 3 separate studies at the 65th Annual Meeting of the American Association for the Study of Liver Diseases last week in Boston. HCV is the leading

Read more
  • Can Mesalamine Prevent Diverticulitis Recurrence?

Can Mesalamine Prevent Diverticulitis Recurrence?

Mesalamine is no better than placebo in preventing recurrent diverticulitis, and is not recommended for its treatment, researchers conclude from 2 international phase 3 studies. The findings are published in the October issue of Gastroenterology. Diverticular disease is characterized by formation of small pouches (diverticula) that push outward through weak spots in the colon wall.  Diverticulitis

Read more

FDA Approves New Obesity Drug

The US Food and Drug Administration (FDA) approved the third new prescription drug for obesity since 2012. The drug, Contrave, to be used along with a low-calorie diet and exercise regimen, was approved for treatment of obese adults (body mass index [BMI] of 30 or greater) or overweight adults (BMI

Read more

Podcast: Efficacy of Vedolizumab in Patients with Moderately to Severely Active Crohn’s disease

Listen to Bruce Sands discuss his article in the September issue of Gastroenterology discussing results from placebo-controlled, phase 3 double-blind trial of the efficacy of vedolizumab  in patients with moderately to severely active Crohn’s disease, including those for whom previous anti-TNF treatment had failed. Sands et al. report that vedolizumab, an antibody against the integrin α4β7, is no more effective

Read more
  • A Window of Opportunity for Treating Patients with Cirrhosis

A Window of Opportunity for Treating Patients with Cirrhosis

Despite the ability of nonselective β blockers (NSBBs) to reduce portal pressure and lower the risk of variceal hemorrhage in patients with cirrhosis, these drugs have detrimental effects on those who have developed spontaneous bacterial peritonitis, researchers show in the June issue of Gastroenterology. Variceal hemorrhage, the most common lethal complication of

Read more

In Treating Crohn’s Disease, Earlier is Better

Patients receiving medical therapies when they have more complicated stages of Crohn’s disease (CD) are more likely to require surgery, researchers report in the March issue of Clinical Gastroenterology and Hepatology. The disease is most-effectively treated by drugs at its early, inflammatory stages. Patients have a 40%–71% risk for requiring

Read more

How Does an Antibiotic Reduce Symptoms of IBS?

Rifaximin alters the intestinal microbiota to prevent inflammation and visceral hyperalgesia in stressed rats, according to the February issue of Gastroenterology. These findings could explain the ability of this antibiotic to relieve symptoms of irritable bowel syndrome (IBS) in patients. Rifaximin is a broad-spectrum antibiotic that has been approved by

Read more

Are IBD Drugs Safe During Pregnancy?

Researchers find no evidence that inflammatory bowel disease (IBD) during pregnancy, or medical treatment for IBD during pregnancy, increases risk for congenital abnormalities in children. The findings, based on a large database analysis, are published in the January issue of Gastroenterology. IBD frequently affects women of reproductive age, and is often

Read more

A New Drug for Diabetes and Fatty Liver Disease?

Obeticholic acid (OCA)—an agonist of the farnesoid X receptor (FXR)— increases insulin sensitivity and reduces markers of liver inflammation and fibrosis in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD), according to a study published in the September issue of Gastroenterology. Type 2 diabetes mellitus and

Read more

Are Patients Receiving the Latest Anti-HCV Drugs?

Less than 20% of patients infected with the most common Hepatitis C virus (HCV) genotype receive the latest drugs approved by the US Food and Drug Administration (FDA), according to the August issue of Clinical Gastroenterology and Hepatology. This low percentage could result from concerns of side effects or patient

Read more